Association of ADP-Induced Whole-Blood Platelet Aggregation with Serum Low-Density Lipoprotein Cholesterol in Patients with Coronary Artery Disease When Receiving Maintenance Ticagrelor-Based Dual Antiplatelet Therapy

• Published in: Journal of clinical medicine Vol. 12; no. 13; p. 4530
• Main Authors: Chyrchel, Bernadeta, Kruszelnicka, Olga, Wieczorek-Surdacka, Ewa, Surdacki, Andrzej
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 06.07.2023; MDPI
• Subjects: Acute coronary syndromes; Adenosine diphosphate; Age; Blood platelets; Cardiovascular disease; Cholesterol; Cholesterol, LDL; Clinical medicine; Coronary heart disease; Diagnosis; Dosage and administration; Drug therapy; Health aspects; Heart attacks; Hemoglobin; Kinases; Lipoproteins; Measurement; Patient outcomes; Physiological aspects; Plasma; Software; Ticagrelor; Poland; United States > US; Germany; dual antiplatelet therapy; platelet reactivity; ticagrelor; LDL cholesterol; P-selectin
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm12134530

The degree of platelet inhibition in patients undergoing dual antiplatelet therapy (DAPT) affects cardiovascular outcomes after acute coronary syndromes (ACS) and/or percutaneous coronary intervention. Our aim was to search for correlates of residual ex vivo platelet reactivity and circulating soluble P-selectin (sP-selectin), an index of in vivo platelet activation, in patients being treated by DAPT with ticagrelor. Adenosine diphosphate (ADP)-induced platelet aggregability (by multiple electrode aggregometry) and plasma sP-selectin were estimated in 62 stable post-ACS subjects (46 men and 16 women; mean age: 64 ± 10 years; 30 with type 2 diabetes (T2DM)) undergoing maintenance DAPT with ticagrelor and aspirin. These patients did not exhibit heart failure or other relevant coexistent diseases except for properly controlled T2DM, mild renal insufficiency, and hypertension. We also assessed this in 64 subjects on clopidogrel-based DAPT matched for age, sex, and T2DM status. ADP-induced platelet aggregation was below the optimal levels (190-460 arbitrary units (AU) * min) in most patients receiving ticagrelor-based DAPT, especially in those with below-median (<1.9 mmol/L) serum concentrations of low-density lipoprotein cholesterol (LDL-c) (128 ± 61 vs. 167 ± 73 AU * min for below-median and above-median LDL-c, respectively, = 0.025). In contrast, platelet reactivity did not differ by LDL-c on clopidogrel-based DAPT (246 ± 101 vs. 268 ± 108 AU * min for below-median and above-median LDL-c, respectively, > 0.4). Plasma sP-selectin was found to be unrelated to serum LDL-c when receiving DAPT with ticagrelor ( > 0.4) or clopidogrel ( > 0.8). In conclusion, our preliminary observational study suggests the association of lower residual ex vivo platelet aggregability with better LDL-c control in patients undergoing ticagrelor-based maintenance DAPT, which does not appear to be reflected by plasma sP-selectin. Whether the serum LDL-c level should be considered among the factors affecting the degree of platelet inhibition for those treated with ticagrelor-based DAPT needs to be investigated in larger studies.